Co-Diagnostics (CODX)

• Market cap: $11.8M
• 1 day: -2.01%
• 5 days: -5.08%
• 1 month: 13.37%
• 3 months: -55.57%
• 6 months: -71.23%
• Year to date: -51.43%
• 1 year: -69.74%
• 5 years: -96.90%
• 10 years: -93.96%
• Sector: Healthcare
• Industry: Medical Devices

About: Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Employees: 132

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

4.09% more ownership

Funds ownership: 13.83% [Q3] → 17.92% (+4.09%) [Q4]

3% more funds holding

Funds holding: 36 [Q3] → 37 (+1) [Q4]

22% less capital invested

Capital invested by funds: $5.52M [Q3] → $4.3M (-$1.22M) [Q4]

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

68% less call options, than puts

Call options by funds: $97K | Put options by funds: $299K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1 185% upside
• Avg. target: $5.50 1,467% upside
• High target: $10 2,749% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

D. Boral Capital Jason Kolbert 28% 1-year accuracy 107 / 376 met price target	2,749% upside $10	Buy Initiated	28 Apr 2025
HC Wainwright & Co. Yi Chen 33% 1-year accuracy 57 / 173 met price target	185% upside $1	Neutral Maintained	28 Mar 2025